Adoptive immunotherapy using T cells expressing chimeric antigen receptors (CARs) has produced remarkable clinical outcomes. However, much of the mechanisms of action, such as the development of memory responses and sources of immune cytokines, remain elusive largely due to the challenge of characterizing human CAR T cell function in vivo. Creative Biolabs has established a humanized mouse (hu-mouse) model with a functional human immune system and genetically-matched (autologous) Lung malignancy that permits modeling of FAP-targeted CAR T cell therapy in immunocompetent hosts without allogeneic or xenogeneic immune responses. Our anti-FAP CAR T cells are prepared from freshly isolated T lymphocytes in a syngeneic mouse model, followed by ex vivo transduction with anti-FAP CAR lentiviral particles and amplification process to generate CAR T cells. These humanized CD34+ mice-derived CAR-T cells offer many advantages including permitting the evaluation of antitumor responses in immunocompetent NSG hosts, testing human CAR-T constructs against human primary malignance, and preclinical evaluation of CAR T cell therapies.